Active — Not RecruitingNot Applicable

Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC

Italy40 participantsStarted 2022-11-07

Plain-language summary

The study aim to evaluate whether some substances produced by muscle or adipose tissue may play a role in the course of the disease by interfering with the effectiveness of therapies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with NSCLC in advanced stage (IIIB, IV) * Patients eligible for the treatment with single-agent immunotherapy (Pembrolizumab), or a chemo-immunotherapy combination among the approved ones for I line * Obtainment of the informations related to medical history and the possibility to have an adequate follow up * Obtainment of the informed consent * Age ≥ 18 years Exclusion Criteria: * Patients with psychiatric alterations, neurological diseases or other condistions that could not allow adhesion to study protocol and the obtainment of the ICF

What they're measuring

Study of serum levels of molecules functionally involved in cachexia/anorexia and sarcopenia, markers of inflammation and markers of aging in patients with NSCLC

Timeframe: The concentration of the respective molecules between the baseline sample and the sample taken after 3 months of treatment will be compared

Trial details

NCT IDNCT06808113

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-07

View on ClinicalTrials.gov More Non Small Cell Lung Cancer trials